---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-018688"
form_type: "8-K"
ticker: "DWTX"
cik: "0001818844"
company_name: "Dogwood Therapeutics, Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:22:58.104250+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Virios Q3 net loss narrows to $1.2M; secures FDA guidance for IMC-1 Phase 3

## Summary
- Net loss $1.2M ($0.06/share) vs $2.6M ($0.28/share) in Q3 2022; cash $4.8M.
- R&D expenses fell to $0.4M from $1.6M on lower clinical trial costs.
- FDA guidance secured for IMC-1 Phase 3 in fibromyalgia; partnership discussions underway.
- Briefing materials submitted to FDA for IMC-2 IND to treat Long-COVID.
- Cash runway expected into Q3 2024 through expense management.

## SEC filing metadata
- accession: 0001558370-23-018688
- form_type: 8-K
- ticker: DWTX
- cik: 0001818844
- company_name: Dogwood Therapeutics, Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818844/000155837023018688/0001558370-23-018688-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818844/000155837023018688/tmb-20231113x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-018688
- JSON: https://secwatch.observer/filing/0001558370-23-018688.json
- Plain text: https://secwatch.observer/filing/0001558370-23-018688.txt

## Key facts
- Earnings Releases
  Dogwood Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income $1.2 million, or $0.06 basic and diluted net loss per share, EPS $0.06 basic and diluted net loss per share.
  - Period: the third quarter ended September 30, 2023
  - Net income: $1.2 million, or $0.06 basic and diluted net loss per share
  - EPS: $0.06 basic and diluted net loss per share
  - Result: reported results
  source text: On November 13, 2023, Virios Therapeutics, Inc. (the “Company”) issued a press release announcing the results of operations for the third quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818844/000155837023018688/0001558370-23-018688-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.